Close Menu

NEW YORK (GenomeWeb) — Finnish diagnostics firm Mobidiag said today that it received CE-IVD marking for its Novodiag CarbaR+ test for carbapenemase-producing enterobacteriaceae (CPE), a bacteria resistant to carbapenem antibiotics.

The multiplex qPCR- and microarray-based test detects CPE and associated resistance markers, as well as a plasmid-mediated resistance for colistin, a last-resort antibiotic for many infections. It runs on the company's automated Novodiag system and produces results within 80 minutes.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.